Alto Neuroscience Inc. (ANRO)
NYSE: ANRO
· Real-Time Price · USD
2.21
0.02 (0.91%)
At close: May 09, 2025, 3:59 PM
2.27
2.71%
After-hours: May 09, 2025, 05:46 PM EDT
0.91% (1D)
| Bid | 2.17 |
| Market Cap | 59.83M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -61.43M |
| EPS (ttm) | -2.5 |
| PE Ratio (ttm) | -0.88 |
| Forward PE | -0.73 |
| Analyst | Buy |
| Ask | 2.32 |
| Volume | 118,174 |
| Avg. Volume (20D) | 326,552 |
| Open | 2.23 |
| Previous Close | 2.19 |
| Day's Range | 2.19 - 2.25 |
| 52-Week Range | 1.60 - 17.55 |
| Beta | 1.87 |
About ANRO
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol ANRO
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for ANRO stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts1 month ago
+25.56%
Alto Neuroscience shares are trading higher after ...
Unlock content with
Pro Subscription
6 months ago
-69.99%
Alto Neuroscience shares are trading lower after the company announced topline results from a Phase 2b trial evaluating ALTO-100 as a treatment for major depressed disorder did not meet its primary endpoint.
2 weeks ago · businesswire.com
Alto Neuroscience to Participate in the JonesResearch Virtual CNS DayMOUNTAIN VIEW, Calif.--(BUSINESS WIRE)---- $ANRO #PrecisionPsychiatry--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel pre...
2 months ago · businesswire.com
Alto Neuroscience to Participate in Upcoming Investor ConferencesMOUNTAIN VIEW, Calif.--(BUSINESS WIRE)---- $ANRO #PrecisionPsychiatry--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel pre...
